Ost-müük Accelerate Diagnostics, Inc. - AXDX CFD
Lisa lemmikuks- Kokkuvõte
- Ajaloolised andmed
- Sündmused
- Tuluaruanne
- Bilanss
- Rahavood
- Omand
Kauplemistingimused
| Hinnavahe | - | ||||||||
|
Pika positsiooni ööpäeva tasu
Long position overnight fee
Mine platvormile | -0.025457% | ||||||||
|
Lühikese positsiooni ööpäeva tasu
Short position overnight fee
Mine platvormile | 0.003235% | ||||||||
| Ööpäeva tasu aeg | 21:00 (UTC) | ||||||||
| Min kauplemise kogus | 1 | ||||||||
| Valuuta | USD | ||||||||
| Tagatis | 20% | ||||||||
| Aktsiabörs | United States of America | ||||||||
| Kauplemise vahendustasu | 0% |
*Information provided by Capital.com
Accelerate Diagnostics Inc ESG Risk Ratings
High Medium Low Negligible
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Võtmestatistika
| Eelmine sulgemine* | N/A |
| Avatud* | N/A |
| Aastane muutus* | N/A |
| Päeva ulatus* | N/A |
| 52 nädala ulatus | 0.45-3.74 |
| Keskmine maht (10 päeva) | 177.40K |
| Keskmine maht (3 kuud) | 6.38M |
| Turukapitalisatsioon | 73.65M |
| P/E suhtarv | -100.00K |
| Ringluses olevad aktsiad | 99.83M |
| Tulu | 12.61M |
| EPS | -0.75 |
| Dividendid (% kasumist) | N/A |
| Beeta | 1.20 |
| Järgmine tuluaruande kuupäev | Aug 14, 2023 |
Kõigi andmete allikas on Refinitiv, välja arvatud tärniga märgitud, kus *-ga andmed on esitanud Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Sulgemishind | Change (%) | Avamishind | High | Low |
|---|
Accelerate Diagnostics, Inc. Events
| Kellaaeg (UTC) (UTC) | Riik | Sündmus |
|---|---|---|
| Monday, August 14, 2023 | ||
| Kellaaeg (UTC) (UTC) 12:30 | Riik US
| Sündmus Q2 2023 Accelerate Diagnostics Inc Earnings Release Q2 2023 Accelerate Diagnostics Inc Earnings ReleaseForecast -Previous - |
| Monday, November 13, 2023 | ||
| Kellaaeg (UTC) (UTC) 10:59 | Riik US
| Sündmus Q3 2023 Accelerate Diagnostics Inc Earnings Release Q3 2023 Accelerate Diagnostics Inc Earnings ReleaseForecast -Previous - |
- Aastas
- Kvartalis
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Kogutulu | 12.752 | 11.782 | 11.165 | 9.297 | 5.67 |
| Tulu | 12.752 | 11.782 | 11.165 | 9.297 | 5.67 |
| Kogu tegevuskulu | 71.992 | 73.549 | 74.865 | 82.128 | 86.039 |
| Müük/Üldine/admin kulud, kokku | 39.193 | 49.236 | 46.904 | 51.886 | 54.014 |
| Uuringud ja arendus | 26.915 | 21.943 | 21.255 | 25.345 | 26.838 |
| Depreciation / Amortization | 2 | ||||
| Tulud majandustegevusest | -59.24 | -61.767 | -63.7 | -72.831 | -80.369 |
| Intressitulud (kulu), muud tulud, neto | -3.103 | -15.87 | -14.443 | -11.571 | -7.718 |
| Netotulu enne makse | -62.57 | -77.657 | -78.203 | -84.416 | -88.115 |
| Netotulu pärast makse | -62.493 | -77.702 | -78.208 | -84.305 | -88.326 |
| Netotulu enne erikulusid | -62.493 | -77.702 | -78.208 | -84.305 | -88.326 |
| Netotulu | -62.493 | -77.702 | -78.208 | -84.305 | -88.326 |
| Arvestatav tulu, v a erikulud | -62.493 | -77.702 | -78.208 | -84.305 | -88.326 |
| Arvestatav tulu, koos erikuludega | -62.493 | -77.702 | -78.208 | -84.305 | -88.326 |
| Jaotamisele kuuluv netotulu | -62.493 | -77.702 | -78.208 | -84.305 | -88.326 |
| Keskmine jaotamisele kuuluv aktsia kohta | 82.161 | 61.727 | 56.01 | 54.506 | 54.494 |
| Jaotatav EPS, v a erakorralised kulud | -0.76062 | -1.2588 | -1.39632 | -1.54671 | -1.62084 |
| Dividends per Share - Common Stock Primary Issue | |||||
| Jaotamisele kuuluv normaal-EPS | -0.78882 | -1.31454 | -1.39632 | -1.54671 | -1.62084 |
| Kulud, Kokku | 9.449 | 7.663 | 6.706 | 4.897 | 3.187 |
| Brutokasum | 3.303 | 4.119 | 4.459 | 4.4 | 2.483 |
| Muud, neto | -0.227 | -0.02 | -0.06 | -0.014 | -0.028 |
| Ootamatud kulutused (tulu) | -3.565 | -5.293 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Kogutulu | 2.812 | 2.972 | 2.96 | 3.861 | 2.958 |
| Tulu | 2.812 | 2.972 | 2.96 | 3.861 | 2.958 |
| Kulud, Kokku | 1.801 | 2.131 | 2.381 | 2.781 | 2.156 |
| Brutokasum | 1.011 | 0.841 | 0.579 | 1.08 | 0.802 |
| Kogu tegevuskulu | 18.874 | 16.932 | 17.921 | 21.651 | 15.487 |
| Müük/Üldine/admin kulud, kokku | 10.105 | 8.771 | 8.255 | 11.493 | 10.673 |
| Uuringud ja arendus | 6.968 | 6.03 | 7.285 | 7.576 | 6.024 |
| Tulud majandustegevusest | -16.062 | -13.96 | -14.961 | -17.79 | -12.529 |
| Intressitulud (kulu), muud tulud, neto | -0.778 | -0.705 | -0.886 | -0.626 | -0.886 |
| Muud, neto | 0.045 | -0.021 | -0.049 | -0.107 | -0.05 |
| Netotulu enne makse | -16.795 | -14.686 | -15.896 | -18.523 | -13.465 |
| Netotulu pärast makse | -16.795 | -14.609 | -15.896 | -18.523 | -13.465 |
| Netotulu enne erikulusid | -16.795 | -14.609 | -15.896 | -18.523 | -13.465 |
| Netotulu | -16.795 | -14.609 | -15.896 | -18.523 | -13.465 |
| Arvestatav tulu, v a erikulud | -16.795 | -14.609 | -15.896 | -18.523 | -13.465 |
| Arvestatav tulu, koos erikuludega | -16.795 | -14.609 | -15.896 | -18.523 | -13.465 |
| Jaotamisele kuuluv netotulu | -16.795 | -14.609 | -15.896 | -18.523 | -13.465 |
| Keskmine jaotamisele kuuluv aktsia kohta | 98.301 | 97.497 | 87.011 | 76.231 | 67.755 |
| Jaotatav EPS, v a erakorralised kulud | -0.17085 | -0.14984 | -0.18269 | -0.24299 | -0.19873 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Jaotamisele kuuluv normaal-EPS | -0.17085 | -0.14984 | -0.18269 | -0.2456 | -0.24841 |
| Ootamatud kulutused (tulu) | 0 | 0 | 0 | -0.199 | -3.366 |
- Aastas
- Kvartalis
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Käibevarad kokku | 56.014 | 73.331 | 81.987 | 121.852 | 177.64 |
| Raha ja lühiajalised investeeringud | 45.561 | 63.618 | 68.269 | 108.451 | 166.478 |
| Raha ja ekvivalendid | 34.905 | 39.898 | 35.781 | 61.014 | 66.26 |
| Lühiajalised investeeringud | 10.656 | 23.72 | 32.488 | 47.437 | 100.218 |
| Laekumata arved, neto | 2.416 | 2.32 | 1.55 | 3.222 | 1.86 |
| Accounts Receivable - Trade, Net | 2.416 | 2.32 | 1.55 | 3.222 | 1.86 |
| Prepaid Expenses | 0.818 | 0.768 | 1.172 | 0.955 | 0.98 |
| Other Current Assets, Total | 2.025 | 1.558 | 1.78 | 1.165 | 0.576 |
| Total Assets | 65.015 | 83.047 | 93.425 | 134.424 | 185.265 |
| Property/Plant/Equipment, Total - Net | 7.759 | 7.899 | 9.318 | 11.822 | 7.303 |
| Property/Plant/Equipment, Total - Gross | 18.58 | 18.698 | 20.153 | 21.687 | 16.014 |
| Accumulated Depreciation, Total | -10.821 | -10.799 | -10.835 | -9.865 | -8.711 |
| Intangibles, Net | 0.114 | ||||
| Total Current Liabilities | 66.557 | 6.945 | 6.969 | 8.162 | 7.763 |
| Accounts Payable | 4.501 | 1.983 | 1.29 | 2.351 | 1.322 |
| Accrued Expenses | 3.983 | 4.431 | 4.75 | 5.54 | 6.224 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 57.526 | 0.08 | 0.553 | ||
| Other Current Liabilities, Total | 0.547 | 0.451 | 0.376 | 0.271 | 0.217 |
| Total Liabilities | 87.279 | 118.118 | 156.237 | 141.803 | 127.89 |
| Total Long Term Debt | 17.64 | 107.984 | 145.87 | 130.043 | 120.074 |
| Capital Lease Obligations | 0.782 | ||||
| Other Liabilities, Total | 3.082 | 3.189 | 3.398 | 3.598 | 0.053 |
| Total Equity | -22.264 | -35.071 | -62.812 | -7.379 | 57.375 |
| Preferred Stock - Non Redeemable, Net | 0.004 | 0.004 | 0 | 0 | 0 |
| Common Stock | 0.097 | 0.068 | 0.058 | 0.055 | 0.054 |
| Additional Paid-In Capital | 630.341 | 580.652 | 475.072 | 452.344 | 432.885 |
| Retained Earnings (Accumulated Deficit) | -607.239 | -570.668 | -492.966 | -414.653 | -330.348 |
| Other Equity, Total | -0.4 | -0.06 | 0.091 | -0.058 | -0.149 |
| Total Liabilities & Shareholders’ Equity | 65.015 | 83.047 | 93.425 | 134.424 | 185.265 |
| Total Common Shares Outstanding | 97.4775 | 67.649 | 57.6079 | 54.7088 | 54.2319 |
| Total Inventory | 5.194 | 5.067 | 9.216 | 8.059 | 7.746 |
| Other Long Term Assets, Total | 1.242 | 1.817 | 2.12 | 0.75 | 0.208 |
| Long Term Debt | 16.858 | 107.984 | 145.87 | 130.043 | 120.074 |
| Treasury Stock - Common | -45.067 | -45.067 | -45.067 | -45.067 | -45.067 |
| Total Preferred Shares Outstanding | 3.95455 | 3.95455 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Käibevarad kokku | 42.834 | 56.014 | 66.272 | 48.059 | 61.111 |
| Raha ja lühiajalised investeeringud | 31.865 | 45.561 | 55.394 | 36.772 | 50.376 |
| Raha ja ekvivalendid | 29.408 | 34.905 | 38.987 | 4.581 | 13.654 |
| Lühiajalised investeeringud | 2.457 | 10.656 | 16.407 | 32.191 | 36.722 |
| Laekumata arved, neto | 2.427 | 2.416 | 2.393 | 2.935 | 2.114 |
| Accounts Receivable - Trade, Net | 2.427 | 2.416 | 2.393 | 2.935 | 2.114 |
| Total Inventory | 5.27 | 5.194 | 5.392 | 5.304 | 5.505 |
| Prepaid Expenses | 1.697 | 0.818 | 1.119 | 1.429 | 1.522 |
| Other Current Assets, Total | 1.575 | 2.025 | 1.974 | 1.619 | 1.594 |
| Total Assets | 51.002 | 65.015 | 75.847 | 58.726 | 70.357 |
| Property/Plant/Equipment, Total - Net | 7.073 | 7.759 | 7.952 | 8.816 | 7.455 |
| Property/Plant/Equipment, Total - Gross | 18.208 | 18.58 | 18.772 | 19.816 | 18.338 |
| Accumulated Depreciation, Total | -11.135 | -10.821 | -10.82 | -11 | -10.883 |
| Other Long Term Assets, Total | 1.095 | 1.242 | 1.623 | 1.851 | 1.791 |
| Total Current Liabilities | 68.125 | 66.557 | 66.084 | 66.929 | 113.875 |
| Accounts Payable | 3.524 | 4.501 | 2.819 | 2.221 | 2.717 |
| Accrued Expenses | 6.425 | 3.983 | 5.383 | 7.132 | 4.941 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 57.708 | 57.526 | 57.358 | 57.241 | 105.819 |
| Other Current Liabilities, Total | 0.468 | 0.547 | 0.524 | 0.335 | 0.398 |
| Total Liabilities | 89.727 | 87.279 | 85.835 | 120.69 | 126.413 |
| Total Long Term Debt | 18.135 | 17.64 | 16.997 | 51.007 | 9.541 |
| Long Term Debt | 17.43 | 16.858 | 16.299 | 49.624 | 9.377 |
| Other Liabilities, Total | 3.467 | 3.082 | 2.754 | 2.754 | 2.997 |
| Total Equity | -38.725 | -22.264 | -9.988 | -61.964 | -56.056 |
| Preferred Stock - Non Redeemable, Net | 0.004 | 0.004 | 0.004 | 0.004 | 0.004 |
| Common Stock | 0.1 | 0.097 | 0.097 | 0.08 | 0.069 |
| Additional Paid-In Capital | 630.903 | 630.341 | 627.853 | 560.185 | 547.381 |
| Retained Earnings (Accumulated Deficit) | -624.034 | -607.239 | -592.63 | -576.734 | -558.211 |
| Treasury Stock - Common | -45.067 | -45.067 | -45.067 | -45.067 | -45.067 |
| Other Equity, Total | -0.631 | -0.4 | -0.245 | -0.432 | -0.232 |
| Total Liabilities & Shareholders’ Equity | 51.002 | 65.015 | 75.847 | 58.726 | 70.357 |
| Total Common Shares Outstanding | 99.6283 | 97.4775 | 97.241 | 79.7014 | 68.7116 |
| Total Preferred Shares Outstanding | 3.95455 | 3.95455 | 3.95455 | 3.95455 | 3.95455 |
| Capital Lease Obligations | 0.705 | 0.782 | 0.698 | 1.383 | 0.164 |
- Aastas
- Kvartalis
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Netotulu/algväärtus | -62.493 | -77.702 | -78.208 | -84.305 | -88.326 |
| Raha majandustegevusest | -48.728 | -47.323 | -50.394 | -64.794 | -67.756 |
| Raha majandustegevusest | 3 | 2.518 | 2.997 | 2.602 | 2.561 |
| Amortization | |||||
| Mittelikviidsed varad | 8.512 | 27.963 | 28.162 | 22.997 | 21.328 |
| Muutused tööjõus | 2.253 | -0.102 | -3.345 | -6.088 | -3.319 |
| Tulu investeeringutelt | 12.417 | 8.304 | 13.606 | 52.811 | -20.138 |
| Kapitalikulutused | -0.554 | -0.603 | -1.362 | -0.33 | -0.998 |
| Muud rahavood investeeringutelt, kokku | 12.971 | 8.907 | 14.968 | 53.141 | -19.14 |
| Rahavood investeeringutelt | 31.63 | 43.226 | 11.633 | 6.823 | 125.771 |
| Rahavoogudesse investeerimine | -0.192 | -1.24 | 0 | 0 | -4.992 |
| Aktsiate emiteerimine (tagasiost), neto | 33.103 | 44.826 | 6.421 | 6.823 | -40.737 |
| Laenu väljastamine (kustutamine), neto | -1.281 | -0.36 | 5.212 | 0 | 171.5 |
| Muutused valuutakursside kõikumisest | -0.312 | -0.09 | -0.078 | -0.086 | -0.13 |
| Rahaline kogumuutus | -4.993 | 4.117 | -25.233 | -5.246 | 37.747 |
| Cash Taxes Paid | 0 | 0 | 0.043 | 0.041 | 0.651 |
| Makstud intressid | 2.214 | 4.288 | 4.288 | 4.288 | 2.001 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -16.795 | -62.493 | -47.884 | -31.988 | -13.465 |
| Cash From Operating Activities | -13.367 | -48.728 | -39.178 | -25.605 | -12.606 |
| Cash From Operating Activities | 0.802 | 3 | 2.207 | 1.435 | 0.616 |
| Non-Cash Items | 1.27 | 8.512 | 5.475 | 4.078 | -0.024 |
| Cash Taxes Paid | 0 | ||||
| Cash Interest Paid | 0 | 2.214 | 2.214 | 1.506 | |
| Changes in Working Capital | 1.356 | 2.253 | 1.024 | 0.87 | 0.267 |
| Cash From Investing Activities | 8.209 | 12.417 | 6.575 | -9.213 | -13.641 |
| Capital Expenditures | -0.012 | -0.554 | -0.446 | -0.447 | -0.447 |
| Other Investing Cash Flow Items, Total | 8.221 | 12.971 | 7.021 | -8.766 | -13.194 |
| Cash From Financing Activities | -0.077 | 31.63 | 31.756 | -0.28 | 0.077 |
| Issuance (Retirement) of Stock, Net | 0 | 33.103 | 33.063 | 0.144 | 0.077 |
| Foreign Exchange Effects | -0.262 | -0.312 | -0.064 | -0.219 | -0.074 |
| Net Change in Cash | -5.497 | -4.993 | -0.911 | -35.317 | -26.244 |
| Issuance (Retirement) of Debt, Net | -0.077 | -1.281 | -1.115 | -0.424 | |
| Financing Cash Flow Items | -0.192 | -0.192 |
| Investori nimi | Investori liik | Ringluse protsent | Hoitud osakud | Muutus osakutes | Hoidmise kuupäev | Hinnang käibele |
|---|---|---|---|---|---|---|
| Schuler (Jack W) | Individual Investor | 18.8237 | 18792022 | 0 | 2023-03-22 | LOW |
| Griffin Asset Management, Inc. | Investment Advisor/Hedge Fund | 10.2665 | 10249206 | 1679464 | 2023-03-31 | LOW |
| Patience (John) | Individual Investor | 6.8217 | 6810164 | 0 | 2023-03-22 | LOW |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 2.8816 | 2876763 | 17714 | 2023-03-31 | LOW |
| Birchview Capital, LP | Investment Advisor | 2.2562 | 2252388 | 0 | 2023-03-31 | LOW |
| Medical Strategy GmbH | Investment Advisor | 1.744 | 1741047 | -225893 | 2023-01-31 | LOW |
| Oracle Investment Management, Inc. | Investment Advisor/Hedge Fund | 1.5132 | 1510654 | -117423 | 2023-03-31 | MED |
| Alyeska Investment Group, L.P. | Hedge Fund | 1.2411 | 1238986 | 0 | 2023-03-31 | LOW |
| Cannell & Co. | Investment Advisor | 1.1138 | 1111919 | 0 | 2023-03-31 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 0.638 | 636973 | 3219 | 2023-03-31 | LOW |
| Millennium Management LLC | Hedge Fund | 0.598 | 596974 | -159491 | 2023-03-31 | HIGH |
| Mertz (Larry Michael) | Individual Investor | 0.5266 | 525695 | 9356 | 2023-05-22 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.4984 | 497523 | 7042 | 2023-03-31 | LOW |
| Phillips (Jack) | Individual Investor | 0.4935 | 492638 | 9277 | 2023-05-15 | LOW |
| Cladis Investment Advisory, LLC | Investment Advisor | 0.4733 | 472500 | 55500 | 2023-03-31 | LOW |
| AWM Investment Company, Inc. | Investment Advisor/Hedge Fund | 0.4016 | 400944 | -72206 | 2023-03-31 | LOW |
| Tejara Capital Ltd. | Investment Advisor | 0.3632 | 362631 | 100000 | 2023-03-31 | HIGH |
| Belpointe Asset Management LLC | Investment Advisor/Hedge Fund | 0.3455 | 344931 | -87 | 2023-03-31 | MED |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.2472 | 246757 | 0 | 2023-03-31 | LOW |
| Eaton Vance Management | Investment Advisor/Hedge Fund | 0.2236 | 223215 | 0 | 2023-03-31 | MED |
Miks valida Capital.com? Meie numbrid räägivad iseenda eest.
Capital.com Group530K+
Kauplejad
87K+
Igakuiste aktiivsete klientide arv
$46M+
Igakuine investeerimise maht
$31M+
Igakuiselt välja võetud
Kauplemiskalkulaator
Arvutage oma hüpoteetiline võit/kaotus, kui oleksite avanud CFD-tehingu ühel kindlal kuupäeval (valige kuupäev) ja sulgenud teisel kuupäeval (valige kuupäev).
Kauplemise vahendustasu
0
- 1:1
Finantsvõimendus
1:1
- 20
- 100
- 500
- 1000
- 10000
Investeering
Tehingu suurus (võimendus x investeering):
Avamishind
Close
Lühike Pikk
Accelerate Diagnostics, Inc. Company profile
Ettevõttest Accelerate Diagnostics, Inc.
Accelerate Diagnostics, Inc. on vitrodiagnostika ettevõte, mis tegeleb lahenduste pakkumisega, mis parandavad patsientide tulemusi tõsiste infektsioonide diagnoosimise kaudu. Ettevõtte in vitro diagnostikaplatvorm, Accelerate Pheno süsteem kasutab genotüüpset tehnoloogiat nakkusetekitajate identifitseerimiseks (ID) ja fenotüüpset tehnoloogiat antibiootikumitundlikkuse testimiseks (AST), millega määratakse kindlaks, kas elusad bakteri- või seenerakud on konkreetse antibiootikumi suhtes resistentsed või tundlikud. See tuvastab ja identifitseerib haigustekitajad otse ühest patsiendi proovist, millele järgneb identifitseerimistulemuste põhjal antimikroobse tundlikkuse testimine. Accelerate Pheno süsteemil on walk-away automaatika ning see koosneb fikseeritud seadmest ja ühekordselt kasutatavast testikomplektist. Accelerate PhenoTest BC Kit annab identifitseerimis- ja AST-tulemused patsientidele, kellel kahtlustatakse baktereemiat või fungeemiat, mis on mõlemad kõrge haigestumuse ja suremuse riskiga eluohtlikud seisundid.
| Industry: | Advanced Medical Equipment & Technology (NEC) |
3950 S Country Club Rd Ste 470 Bldg 3-307
80203
Tuluaruanne
- Annual
- Quarterly
Teised on vaadanud veel
Kas otsite jätkuvalt vahendajat, keda saab usaldada?
Ühinege 530,000+ kauplejaga üle kogu maailma, kes valisid kauplemiseks veebisaidi Capital.com